Page last updated: 2024-10-30

memantine and Anxiety Disorders

memantine has been researched along with Anxiety Disorders in 3 studies

Anxiety Disorders: Persistent and disabling ANXIETY.

Research Excerpts

ExcerptRelevanceReference
"Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders."9.22Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022)
"Memantine was well tolerated, and there were no serious adverse effects."6.74Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. ( Bystritsky, A; Feusner, JD; Kerwin, L; Saxena, S, 2009)
"Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders."5.22Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022)
"Memantine was well tolerated, and there were no serious adverse effects."2.74Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. ( Bystritsky, A; Feusner, JD; Kerwin, L; Saxena, S, 2009)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Elnaiem, W1
Benmelouka, AY1
Elgendy, AMN1
Abdelgalil, MS1
Brimo Alsaman, MZ1
Mogheeth, A1
Ali, MM1
Yousof, SM1
Yuanyuan, J1
Junyan, Z1
Cuola, D1
Jingjing, C1
Yuhui, S1
Dan, X1
Wei, D1
Yongsheng, Z1
Feusner, JD1
Kerwin, L1
Saxena, S1
Bystritsky, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial[NCT00674219]Phase 317 participants (Actual)Interventional2005-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Psychometric Scores

"Participants in the OCD group were rated using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a standard measure of obsessive-compulsive disorder (OCD) severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 10 items assessing OCD symptoms (e.g. time spent, degree of control, severity). Each item is scored on a scale from 0 (not present) to 4 (severe) [total score range = 0-40] over the previous week. The higher the number on the Y-BOCS, the more severe the symptoms.~Participants in the GAD group were rated using the Hamilton Anxiety Rating Scale (HARS), a standard measure of anxiety severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 14 items assessing anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe." (NCT00674219)
Timeframe: Baseline, 12 weeks

,
Interventionunits on a scale (Mean)
12 weeksBaseline
GAD Group18.8624.3
OCD Group16.427.6

Reviews

1 review available for memantine and Anxiety Disorders

ArticleYear
Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis.
    Human psychopharmacology, 2022, Volume: 37, Issue:5

    Topics: Anxiety Disorders; Autism Spectrum Disorder; Child; Excitatory Amino Acid Antagonists; Humans; Meman

2022

Trials

1 trial available for memantine and Anxiety Disorders

ArticleYear
Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Psychopharmacology bulletin, 2009, Volume: 42, Issue:1

    Topics: Adult; Anxiety Disorders; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middle

2009

Other Studies

1 other study available for memantine and Anxiety Disorders

ArticleYear
Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway.
    Neuroscience letters, 2018, 11-01, Volume: 686

    Topics: Alcoholism; Animals; Anxiety; Anxiety Disorders; Calcium-Calmodulin-Dependent Protein Kinase Type 2;

2018
chemdatabank.com